glp 1 plus insulin Insights into GLP-1 and secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment Discovery, characterization, and clinical development
Description
Methods We obtained the data from PubMed, Scopus, Embase, and Web of Science for all eligible studies, including clinical trials (RCT) and cohorts comparing GLP-1 RAs to placebo or other hypoglycemic agents in patients with HFpEF published until December 31st, 2024
Trial Registration The predefined protocol has been registered in PROSPERO having registration number of CRD42023473991
The first medication in this class (exenatide: Byetta) was FDA approved
Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide hormone that is mainly expressed in the intestine and hypothalamus
Experience safe, effective medical weight loss with proven results that last at Saltz Wellness.
Who This Case Is For
